01/31/23 8:00 AMNasdaq : RAIN conferenceslow floatRain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day ConferenceRain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, todayRHEA-AIneutral
01/23/23 8:00 AMNasdaq : RAIN clinical triallow floatPhase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the registrational Phase 3 MANTRARHEA-AInegative
12/29/22 8:00 AMNasdaq : RAIN low floatRain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex thatRHEA-AIneutral
12/27/22 8:00 AMNasdaq : RAIN conferenceslow floatRain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care ConferenceRain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivatesRHEA-AIneutral
11/23/22 8:00 AMNasdaq : RAIN low floatRain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer SymposiumRain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivatesRHEA-AIneutral
11/18/22 8:00 AMNasdaq : RAIN conferenceslow floatRain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare ConferenceRain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivatesRHEA-AIneutral
11/17/22 1:05 PMNasdaq : RAIN low floatRain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual MeetingRain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivatesRHEA-AIneutral
11/14/22 8:00 AMNasdaq : RAIN conferenceslow floatRain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual ConferenceRain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivatesRHEA-AIneutral
11/10/22 4:05 PMNasdaq : RAIN earningslow floatRain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 – – Phase 3 pivotal MANTRA trial topline data now anticipated in first quarter of 2023 – – Phase 2 MANTRA-2 trial preliminary interim dataRHEA-AIneutral
11/04/22 8:00 AMNasdaq : RAIN offeringlow floatRain Therapeutics Announces $50 Million Registered Offering of Common StockRain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares ofRHEA-AIneutral